Radiotherapy for head and neck cancer: Latest developments and future perspectives

Current Opinion in Oncology

Volumn 18, Issue 3, 2006, Pages 240-246

  Bernier, Jacques ^a   Bentzen, Soeren M ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Altered fractionation; Chemo radiation; Chemotherapy; IMRT; Radiotherapy

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CYTOSTATIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; PLATINUM DERIVATIVE; RADIOSENSITIZING AGENT; TIRAPAZAMINE; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; SKIN INFLAMMATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG DELIVERY SYSTEMS; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 33646684021     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000219252.45467.88     Document Type: Review

References (64)

1. Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1-2N0): surgery or irradiation? Head Neck 2004; 26:127-135.
2. Fletcher GH, Evers W. Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the Head and Neck. Radiology 1970; 95:185-188.
3. Bataini JP, Asselain B, Jaulerry C, et al. A multivariate primary tumor control analysis in 465 patients treated by radical radiotherapy for carcinoma of the tonsillar region: clinical and treatment parameters as prognostic factors. Radiother Oncol 1989; 14:265-277.
4. Wadsley JC, Bentzen SM. Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 60:1405-1409.
5. Ang KK. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol 1998; 8:230-236.
6. Peters U, Ang KK, Thames HD. Altered fractionation schedules. In: Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 2nd ed. Philadelphia: J.B. Lippincott; 1992. pp. 97-113.
7. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25:231-241.
8. Bentzen SM. Quantitative clinical radiobiology. Acta Oncol 1993; 32: 259-275.
9. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44:111-121.
10. Bourhis J, Etessami A, Wilbault P, et al. Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations. Curr Opin Oncol 2004; 16:215-219.
11. Khalil AA, Bentzen SM, Bernier J, et al. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys 2003; 55:568-575.
12. Mendenhall WM, Riggs CE, Amdur RJ, et al. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck. Laryngoscope 2003; 113:546-551.
13. Bourhis J, Audry H, Overgaard J, et al. Meta-analysis of conventional versus altered fractionated radiotherapy: in head and neck squamous cell carcinomas (HNSCC): final analysis. 46th American Society of Therapeutic Radiology and Oncology (ASTRO) meeting, 3-7 October 2004. Atlanta. Int J Rad Oncol Biol Phys 2004; 60 (Suppl):S190-S191.
14. Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44:123-136.
15. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol 1999; 53:219-226.
16. Ang KK, Peters LJ, Weber RS, et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990; 19:1339-1345.
17. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48:7-16.
18. Eisbruch A, Ship JA, Kim HM, Ten Haken RK. Partial irradiation of the parotid gland. Semin Radiat Oncol 2001; 11:234-239.
19. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001; 49:907-916.
20. Bentzen SM. High-tech in radiation oncology: should there be a ceiling? Int J Radiat Oncol Biol Phys 2004; 58:320-330.
21. Hong TS, Tome WA, Chappell RJ, et al. The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61:779-788.
22. Mackie TR, Kapatoes J, Ruchala K, et al. Image guidance for precise conformai radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:89-105.
23. Jaffray DA. Emergent technologies for 3-dimensional image-guided radiation delivery. Semin Radiat Oncol 2005; 15:208-216. This contribution outlines the opportunities offered by the novel techniques of radiotherapy based on image guidance.
24. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146.
25. Vermorken JB. Adjuvant chemotherapy for advanced squamous cell carcinomas of the head and neck. In: Snow GB, Clark JR, editors. Multimodality therapy for head and neck cancer. New York: Georg Thieme Verlag; 1992. pp. 112-126.
26. Herscher LL, Cook JA, Pacelli P, et al. Principles of chemoradiation: theoretical and practical considerations. Oncology 1999; 13:11-22.
27. Eisbruch A, Normolle DP. Testing new chemoradiation regimens for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 61:5-6.
28. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005; 23:1125-1135.
29. Rosenthal DI, Blanco AI. Head and neck squamous cell carcinoma: optimizing the therapeutic index. Expert Rev Anticancer Ther 2005; 5:501-514.
30. Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003; 39:560-571.
31. Bernier J, Bentzen SM. Postoperative treatment of locally advanced head and neck cancers. In: Adelstein DJ, Totowa NJ, editors. Current clinical oncology: squamous cell head and neck cancer. Totowa: Humana Press Inc; 2005. pp. 197-210.
32. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol (in press).
33. Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001; 23:579-589.
34. Bourhis J, Amand C, Pignon JP, On behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. Proc Am Soc Clin Oncol 2004; 22:143.
35. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
36. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
37. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27:843-850.
38. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-7356.
39. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23:5560-5567. This provides an important contribution to the field of targeted therapies.
40. Milas L, Mason K, Hunter N, et al. Enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708.
41. Bonner JA, Giralt J, Harari P, et al. Cetuximab survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase II study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004; 22:143.
42. Bernier J. Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nat Clin Pract Oncol 2005; 2:305-314. In head-and-neck oncology this is a reference review on intensive chemoradiation.
43. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77:18-24. This describes an excellent approach to the predictive value of hypoxia in patients treated with radiotherapy.
44. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46:35-46.
45. Overgaard J, Hansen HS, Andersen AP, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989; 16:1065-1068.
46. Brown JM. The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59:5863-5870.
47. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J Clin Oncol 2005; 23:79-87. This article triggered the interest for novel approaches taking advantage of the presence of hypoxic cells rather than overcoming it.
48. Hicks R, Rischin D, Fisher R, et al. Superiority of tirapazamine- containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning. Proc Am Soc Clin Oncol 2004; 22:143.
49. Chao KS, Ozygit G, Thorsdad WL. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Sem Oncol 2003; 30:101-108.
50. Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 2002; 29:57-60.
51. Hofmeister CC, Stiff PJ. Mucosal protection by cytokines. Curr Hematol Rep 2005; 4:446-465.
52. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16:1318-1324.
53. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798-1804.
54. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000; 57:119-124.
55. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18:1458-1464.
56. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:1161-1171.
57. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. Clin Oncol 2004; 22:4613-4621.
58. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 2004; 22:19-22.
59. Soares HP, Kumar A, Daniels S, et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA 2005; 293: 970-978.
60. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-181.
61. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol 2003; 13:189-202.
62. Ataman OU, Bentzen SM, Wilson GD, et al. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 2004; 40:2734-2741.
63. Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 2004; 10:3745-3754.
64. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005; 6:112-117. The author describes a leading experience in the field of optimization for treatment planning and delivery.